Celecoxib, a selective cyclo-oxygenase-2 inhibitor, enhances the response to preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer. [electronic resource]
Producer: 20030814Description: 2645-50 p. digitalISSN:- 0732-183X
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols
- Carboplatin -- administration & dosage
- Carcinoma, Non-Small-Cell Lung -- drug therapy
- Celecoxib
- Chemotherapy, Adjuvant
- Cyclooxygenase Inhibitors -- administration & dosage
- Dose-Response Relationship, Drug
- Drug Administration Schedule
- Drug Synergism
- Female
- Follow-Up Studies
- Humans
- Lung Neoplasms -- drug therapy
- Male
- Maximum Tolerated Dose
- Middle Aged
- Paclitaxel -- administration & dosage
- Pneumonectomy
- Preoperative Care -- methods
- Pyrazoles
- Sulfonamides -- administration & dosage
- Survival Analysis
- Treatment Outcome
No physical items for this record
Publication Type: Clinical Trial; Clinical Trial, Phase II; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.